Skip to main navigation

Header Nav

Company
Pipeline and Technology
Business Development
Investors
Contact Us

Select Page

Press Releases

Header Nav

Welcome
Financial Information
Financial Fundamentals
Stock Information
- Stock Quote & Chart
- Historic Price Lookup
Filings
- SEC Filings
- Ownership
Corporate Governance
Corporate Presentation
Events
Press Releases
Investor Alerts

Toolkit

Email Alerts
Print Page
Share
RSS Feeds
Contact IR
Search

Press Releases

Year

Apr 18, 2024

Windtree Therapeutics Announces Reverse Stock Split

WARRINGTON, Pa. , April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company’s Board of Directors has

Apr 17, 2024

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa. , April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter

Apr 8, 2024

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

WARRINGTON, Pa. , April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc.

Feb 1, 2024

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

WARRINGTON, Pa. , Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang

Jan 31, 2024

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

WARRINGTON, Pa. , Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has engaged Ladenburg Thalmann & Co.

Jan 25, 2024

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

WARRINGTON, Pa. , Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that the Company entered an Exchange and

Jan 17, 2024

Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for products in the licensed territory Lee’s plans to initiate and fund Phase 3 for istaroxime in acute

Jan 2, 2024

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute heart failure WARRINGTON, Pa. , Jan. 02, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.

YM Twitter Feed